HCV Protease
信号通路图
研究领域
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S1482 | Daclatasvir (BMS-790052) | <1 mg/mL | 148 mg/mL | 148 mg/mL |
| S1538 | Telaprevir (VX-950) | <1 mg/mL | 136 mg/mL | <1 mg/mL |
| S1480 | Lomibuvir (VX-222, VCH-222) | <1 mg/mL | 89 mg/mL | 89 mg/mL |
| S1183 | Danoprevir (ITMN-191) | <1 mg/mL | 144 mg/mL | 144 mg/mL |
| S4935 | Asunaprevir | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S5652 | Elbasvir | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S5394 | Tizoxanide | <1 mg/mL | 27 mg/mL | <1 mg/mL |
| S5402 | Dasabuvir(ABT-333) | <1 mg/mL | 98 mg/mL | <1 mg/mL |
| S5404 | Paritaprevir (ABT-450) | -1 mg/mL | 100 mg/mL | -1 mg/mL |
| S5403 | Ombitasvir (ABT-267) | -1 mg/mL | 100 mg/mL | -1 mg/mL |
| S5307 | PSI-6206 (RO-2433, GS-331007) | 52 mg/mL | 52 mg/mL | 24 mg/mL |
| S5062 | Daclatasvir Digydrochloride | 100 mg/mL | 100 mg/mL | 100 mg/mL |
| S5015 | Simeprevir | <1 mg/mL | 100 mg/mL | 4 mg/mL |
| S3800 | Lycorine hydrochloride | -1 mg/mL | 64 mg/mL | -1 mg/mL |
| S3733 | Boceprevir | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S3724 | Velpatasvir | 100 mg/mL | 100 mg/mL | 100 mg/mL |
| S3728 | Grazoprevir | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S7579 | Ledipasvir (GS5885) | <1 mg/mL | 100 mg/mL | 100 mg/mL |
- HCV Protease抑制剂（19）
- 新HCV Protease产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1482 |
Daclatasvir (BMS-790052)Daclatasvir (BMS-790052)是一种高度选择性的HCV NS5A抑制剂，EC50为9-50 pM，在细胞培养中，作用于多种HCV复制基因型和JFH-1基因型2a的感染性病毒。Phase 3。 |
Sensitivity of PR63cc to the combinatory treatment with asunaprevir and daclatasvir. Huh7.5.1 cells infected with PR63cc or JFH1 at an MOI of 0.05 for 3 days were treated with either asunaprevir, daclatasvir or in combination for another 3 days. 40 nM asunaprevir and 0.05 nM daclatasvir, approximately the EC50 concentration of the each inhibitor for JFH1, were used. The antiviral efficiency of each compound was evaluated by quantifying the intracellular HCV RNA by RT-qPCR. Data were expressed as the percentage of mock treatment control. The error bars were calculated from two independent experiments. ns, P > 0.05. *, P < 0.05.
|
|
| S1538 |
Telaprevir (VX-950)Telaprevir (VX-950)是一种丙型肝炎病毒(HCV)NS3-4A丝氨酸蛋白酶抑制剂，IC50为0.354 μM。 |
HCV replicon genotype 1b cells were passaged in the presence of G418 alone (medium 694 control) or G418 with miravirsen, SPC4729 (oligonucleotide negative control) or telaprevir for 28 days in fixed concentrations at a multiple (X) of the EC50 of miravirsen or telaprevir. Colony formation was assessed by staining surviving cells with crystal violet.
|
|
| S1480 |
Lomibuvir (VX-222, VCH-222)Lomibuvir (VX-222, VCH-222)是一种新型的，有效的，选择性的HCV聚合酶抑制剂，IC50为0.94-1.2 μM，作用于突变型M423T效果低15.3倍，作用于突变型I482L效果低108倍。Phase 2。 |
Genetic barriers of JTK-853, NNI-A, PF-868554, VX-222, PSI-6130, BMS-790052, and TMC435 for Con1. VX-222 and the other DAAs were treated at 1/3xEC90 for 17 days. |
|
| S1183 |
Danoprevir (ITMN-191)Danoprevir (ITMN-191)是一种肽类抑制剂，作用于丙型肝炎病毒(HCV)的NS3/4A蛋白酶，IC50为0.2-3.5 nM，抑制HCV 1A/1B/4/5/6基因型比抑制2B/3A基因型效果高10倍左右。Phase 2。 |
Effects of TNFα, etanercept, and danoprevir on HCV infection in HFLC. Cells (n=6 wells/condition) were treated with TNFα (20 ng/ml) ± etanercept (1 μg/ml), danoprevir (2 μM), or media control before and during infection with Jc1G. Secreted luciferase was measured 96 hours after the start of infection. Box-and-whiskers plot; whiskers represent minimum and maximum values. Values of p were calculated by one-way ANOVA. ***, p < 0.001; ****, p < 0.0001 |
|
| S4935New |
AsunaprevirAsunaprevir是具有口服活性的HCV NS3抑制剂。HCV NS3是病毒复制蛋白加工所必需的蛋白酶。 |
||
| S5720New |
GlecaprevirGlecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. |
||
| S5652New |
ElbasvirElbasvir is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype. |
||
| S5394New |
TizoxanideTizoxanide, a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C. |
||
| S5402New |
Dasabuvir(ABT-333)Dasabuvir(ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. |
||
| S5404New |
Paritaprevir (ABT-450)Paritaprevir (ABT-450)是NS3/4A抑制剂。 |
||
| S5403New |
Ombitasvir (ABT-267)Ombitasvir (ABT-267)是HCV NS5A的抑制剂，具有抗病毒活性。 |
||
| S5307New |
PSI-6206 (RO-2433, GS-331007)PSI-6206 (RO-2433, GS-331007)是有效的HCV RNA依赖性RNA聚合酶抑制剂，靶向NS5B聚合酶。 |
||
| S5062New |
Daclatasvir DigydrochlorideDaclatasvir是一种具有口服活性的抗病毒剂，抑制HCV的NS5A区域，用于治疗慢性遗传型1和3类的HCV感染。 |
||
| S5015New |
SimeprevirSimeprevir一种竞争性的、可逆的、非共价结合的大环hepatitis C virus (HCV) NS3/4A protease抑制剂，直接抑制HCV病毒。它对HCV NS3/4A(genotypes 1a, 1b, 2, 4, 5, and 6)的平均IC50值小于13 nM，而对genotype 3的IC50值为37 nM。 |
||
| S3800New |
Lycorine hydrochlorideLycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity. |
||
| S3733New |
BoceprevirBoceprevir是一种口服的、直接作用于hepatitis C virus (HCV) protease的抑制剂，对NS3蛋白酶的Ki值为14 nM。在治疗慢性肝炎C(genotype 1)中，常与其他抗病毒共同给药。 |
||
| S3724New |
VelpatasvirVelpatasvir是二代NS5A抑制剂，抑制丙型肝炎病毒（HCV）的复制。 |
||
| S3728New |
GrazoprevirGrazoprevir anhydrous is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively. |
||
| S7579 |
Ledipasvir (GS5885)Ledipasvir（GS5885）是一种HCV NS5A polymerase抑制剂，用于治疗丙型肝炎病毒感染。 |
(C) Impact of HCV clearance by DAA treatment on the Nrf2 nuclear translocation. HCV infected Huh-7.5 cells day 12 were given two rounds of antiviral treatment with IFN-α, sofosbuvir, ledipasvir or combination of sofosbuvir plus ledipasvir. After 72 hours, cells were split, and then treated again with the same antiviral agent. After two rounds of antiviral treatment, the expressions of HCV core and pNrf2 were measured by immunostaining.
|
